Myeloid cell influx into the colonic epithelium is associated with disease severity and non-response to anti-Tumor Necrosis Factor Therapy in patients with Ulcerative Colitis.
RNA sequencing
Ulcerative colitis
anti-TNF treatment response
intraepithelial compartment
spatial transcriptomics
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
05 Jun 2023
05 Jun 2023
Historique:
pubmed:
19
6
2023
medline:
19
6
2023
entrez:
19
6
2023
Statut:
epublish
Résumé
Ulcerative colitis (UC) is an idiopathic chronic inflammatory disease of the colon with sharply rising global prevalence. Dysfunctional epithelial compartment (EC) dynamics are implicated in UC pathogenesis although EC-specific studies are sparse. Applying orthogonal high-dimensional EC profiling to a Primary Cohort (PC; n=222), we detail major epithelial and immune cell perturbations in active UC. Prominently, reduced frequencies of mature
Identifiants
pubmed: 37333091
doi: 10.1101/2023.06.02.542863
pmc: PMC10274630
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIDDK NIH HHS
ID : K23 DK111995
Pays : United States
Organisme : NIDDK NIH HHS
ID : RC2 DK122532
Pays : United States
Déclaration de conflit d'intérêts
Competing interests: SM reports receiving research grants from Genentech and Takeda; receiving payment for lectures from Takeda, Genentech, Morphic; and receiving consulting fees from Takeda, Morphic, Ferring and Arena Pharmaceuticals. JM reports receiving consulting fees from Janssen Pharmaceuticals. JFC reports receiving research grants from AbbVie, Janssen Pharmaceuticals, Takeda and Bristol Myers Squibb; receiving payment for lectures from AbbVie, and Takeda; receiving consulting fees from AbbVie, Amgen, AnaptysBio, Allergan, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Celltrion, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Glaxo Smith Kline, Genentech (Roche), Janssen Pharmaceuticals, Kaleido Biosciences, Immunic, Invea, Iterative Scopes, Merck, Landos, Microba Life Science, Novartis, Otsuka Pharmaceutical, Pfizer, Protagonist Therapeutics, Prometheus, Sanofi, Seres, Takeda, Teva, TiGenix, Vifor; and hold stock options in Intestinal Biotech Development. JM reports receiving consulting fees from Janssen Pharmaceuticals. RCU has served as an advisory board member or consultant for AbbVie, Bristol Myers Squibb, Celltrion, Janssen, Pfizer, Roivant, and Takeda; research support from AbbVie, Boehringer Ingelheim, Eli Lily, and Pfizer. MK has served as a consultant for AbbVie, Pfizer, Bristol Myers Squibb, Fresenius, GoodRx.